HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
HCA - HCA Healthcare, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$527.45
DETAILS
HIGH:
$635.00
LOW:
$436.00
MEDIAN:
$530.00
CONSENSUS:
$527.45
UPSIDE:
33.85%
Stock News
HCA Healthcare Colleagues Volunteer More Than 41,800 Hours During Annual Days of Service Initiative
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced the results of its seventh annual We Show Up for Our Communities days of service volunteer initiative. In alignment with National Volunteer Month, HCA Healthcare colleagues across the country donated their time and expertise to help improve the health and well-being of the communities the company serves. “Caring for our communities is at the heart of HCA Healthca.
HCA DCF Analysis: Intrinsic Value $765 vs Price $423
On May 19, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company that has experienced a price performance of -0.8% over the past week, -1
HCA DCF Analysis: Intrinsic Value $765 vs Price $429
On May 08, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company that has seen varied price performance recently. Over the past week, the
HCA Healthcare, Inc. to Present at May Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conference: May 20, 2026, at 11:30am ET at the RBC Global Healthcare Conference A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule or the Invest.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Comerica Bank Sells 3,248 Shares of HCA Healthcare, Inc. $HCA
Comerica Bank reduced its position in shares of HCA Healthcare, Inc. (NYSE: HCA) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,860 shares of the company's stock after selling 3,248 shares during the period. Comerica Bank's holdings in
HCA Healthcare Inc (HCA) Shares Surge 3.1% -- What GF Score of 97 Tells Investors
On April 27, 2026, HCA Healthcare Inc (HCA) shares rose 3.1% today, bringing the current price to $445.77. Over the past year, the stock has experienced a notab
HCA Healthcare Names Cynthia Cifuentes-Finkel Senior Vice President of Marketing and Corporate Affairs
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare (NYSE: HCA) today announced that Cynthia Cifuentes-Finkel has been named senior vice president of marketing and corporate affairs, effective June 8, 2026. She will report to Mike McAlevey, executive vice president, chief legal and administrative officer, and will lead enterprise marketing, corporate communications, and stakeholder engagement in support of HCA Healthcare's enterprise growth priorities. “Cynthia is a strategic and accomplished lea.
These Analysts Slash Their Forecasts On HCA Healthcare After Q1 Results
HCA Healthcare Inc. (NYSE:HCA) posted in-line earnings for the first quarter on Friday.
HCA Announces Proposed Public Offering of Senior Notes
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced that its wholly owned subsidiary, HCA Inc., proposes to offer senior notes, subject to market and other considerations. Actual terms of the senior notes, including maturity, interest rate and principal amount, will depend on market conditions at the time of pricing. HCA Inc. intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of outstanding borrowing.
HCA Healthcare, Inc. $HCA Shares Sold by Calamos Advisors LLC
Calamos Advisors LLC decreased its holdings in HCA Healthcare, Inc. (NYSE: HCA) by 3.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,373 shares of the company's stock after selling 1,964 shares during the quarter. Calamos Advisors LLC's holdings in HCA Healthcare
HCA Healthcare, Inc. (NYSE:HCA) Given Consensus Rating of “Moderate Buy” by Analysts
HCA Healthcare, Inc. (NYSE: HCA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-four ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to
HCA Healthcare Inc (HCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges
Revenue Increase: 4.3% compared to the first quarter last year.Adjusted EBITDA Increase: Almost 2% year-over-year.Diluted Earnings Per Share (Adjusted): Increa
HCA Healthcare: Policy Pressures May Be Limiting Admissions (Upgrade)
HCA Healthcare is upgraded to "Hold" after a 12% pullback, and is now trading near fair value with a 7% free cash flow yield. Q1 results were mixed: EPS matched expectations, revenue grew 4%, but surgical volumes softened and margins retraced 50 bps. Policy headwinds, including Medicaid and ACA subsidy rollbacks, are expected to temper growth to 2%-3% annually over the next several years.
HCA Healthcare, Inc. (HCA) Q1 2026 Earnings Call Transcript
HCA Healthcare, Inc. (HCA) Q1 2026 Earnings Call Transcript
HCA Healthcare Q1 Earnings Miss Estimates on Rising Expenses
HCA's Q1 EPS misses estimates as rising expenses and weaker surgeries weigh despite modest revenue growth and gains in ER visits.
HCA Healthcare (HCA) Faces Decline After Q1 Results and FY26 Guidance
HCA Healthcare (HCA) is experiencing a significant drop in trading following its Q1 earnings report and reaffirmation of FY26 guidance. The mixed results stem p
HCA (HCA) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for HCA (HCA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HCA Healthcare (HCA) Q1 Earnings and Revenues Miss Estimates
HCA Healthcare (HCA) came out with quarterly earnings of $7.15 per share, missing the Zacks Consensus Estimate of $7.17 per share. This compares to earnings of $6.45 per share a year ago.
Price Targets
HCA Healthcare price target lowered to $530 from $560 at Stephens
$530.00
(was $444.76)
Stephens
HCA Healthcare price target lowered to $535 from $546 at Truist
$535.00
(was $432.46)
Truist Financial
HCA Healthcare price target lowered to $520 from $540 at Oppenheimer
$520.00
(was $432.46)
Oppenheimer
HCA Healthcare price target lowered to $534 from $593 at RBC Capital
$534.00
(was $432.46)
RBC Capital
HCA Healthcare price target lowered to $436 from $481 at Wells Fargo
$436.00
(was $432.46)
Wells Fargo
HCA Healthcare price target lowered to $510 from $550 at KeyBanc
$510.00
(was $432.46)
KeyBanc
HCA Healthcare price target lowered to $496 from $551 at Barclays
$496.00
(was $432.46)
Barclays
HCA Healthcare price target lowered to $525 from $590 at Jefferies
$525.00
(was $432.46)
Jefferies
HCA Healthcare price target raised to $635 from $598 at UBS
$635.00
(was $532.30)
UBS
HCA Healthcare price target raised to $541 from $503 at Bernstein
$541.00
(was $501.69)
Bernstein
HCA Healthcare price target raised to $540 from $520 at Mizuho
$540.00
(was $488.27)
Mizuho Securities
HCA Healthcare price target raised to $481 from $452 at Wells Fargo
$481.00
(was $482.53)
Wells Fargo
HCA Healthcare price target raised to $555 from $525 at RBC Capital
$555.00
(was $483.16)
RBC Capital
Bernstein Reiterates Market Perform Rating on HCA Healthcare Inc (HCA)
$503.00
(was $483.76)
KeyBanc
HCA Healthcare price target raised to $598 from $525 at UBS
$598.00
(was $487.53)
UBS
HCA Healthcare price target raised to $540 from $500 at Oppenheimer
$540.00
(was $505.84)
Oppenheimer
HCA Healthcare price target raised to $588 from $525 at Cantor Fitzgerald
$588.00
(was $505.84)
UBS
HCA Healthcare price target raised to $550 from $500 at KeyBanc
$550.00
(was $505.84)
KeyBanc
HCA Healthcare price target raised to $551 from $494 at Barclays
$551.00
(was $505.84)
Andrew Mok
·
Barclays
HCA Healthcare price target raised to $500 from $475 at KeyBanc
$500.00
(was $465.44)
KeyBanc